Business Context and Reporting Period
This Form 8-K was filed by Vistagen Therapeutics, Inc. on August 4, 2026. The report addresses a regulatory matter concerning the continued listing of the Company's Common Stock (trading symbol: VTGN) on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on compliance with Nasdaq listing standards regarding stock price.
Material Changes and Listing Status
- Extension Granted: Nasdaq granted the Company a 180-day extension to regain compliance with the Minimum Bid Price Requirement.
- Compliance Deadline: The Company must achieve a minimum bid price of $1.00 per share by February 1, 2027.
- Current Status: As of the filing date, the Company has not yet regained compliance. The stock remains listed on the Nasdaq Capital Market during this extension period.
- Background: The deficiency was originally identified on February 6, 2026, after the stock failed to meet the $1.00 minimum bid price for 30 consecutive business days.
Outlook, Risks, and Contingencies
- Delisting Risk: If the Company fails to regain compliance by February 1, 2027, Nasdaq will issue a notification that the Common Stock is subject to delisting.
- Appeal Process: In the event of a delisting determination, the Company may appeal to a Nasdaq Hearing Panel. The filing explicitly states there can be no assurance that such an appeal would be successful.
- Management Intent: The Company has advised Nasdaq of its intent to cure the deficiency within the granted extension period.
Investor Verification Checklist
- Verify the current trading price of VTGN relative to the $1.00 minimum bid price requirement.
- Monitor the Company's progress toward compliance before the February 1, 2027 deadline.
- Review any future filings regarding potential reverse stock splits or other corporate actions intended to address the bid price deficiency.
- Check for any subsequent 8-K filings if the Company fails to meet the February 1, 2027 deadline.